An unusual presentation of primary rib non hodgkins lymphoma masquerading as male breast cancer (original) (raw)

Primary Hodgkin Lymphoma of RIB -A Rare Case Report

https://www.ijhsr.org/IJHSR\_Vol.6\_Issue.1\_Jan2016/87.pdf, 2016

Hodgkin lymphoma is a well known lymphoproliferative disease which presents as a nodal lesion with secondary involvement of extranodal sites like skin, bone or any other organ system. This case report is regarding a 55 year old female presenting with osteolytic mass in the fifth rib. Imaging studies revealed no other associated findings like organomegaly or lymphadenopathy. Histological and immunohistochemical findings were in favour of Primary extra nodal Hodgkin lymphoma nodular sclerosis type.

Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients

Turkish Journal of …

Objective: Non-Hodgkin's lymphoma (NHL) of bone is a rare entity. The most common histological subtype is diffuse large B cell lymphoma (DLBCL). The major presenting symptoms are soft tissue swelling, bone pain and pathological fracture. Treatment options are chemotherapy, radiotherapy, surgery, or a combination of these modalities. Materials and Methods: We retrospectively analyzed the 18 patients (11 females, 7 males) with NHL of bone who were diagnosed and treated between 1995-2005. The median age was 56.5 years. The median duration of symptoms was 4.5 months. The bone pain was the first symptom in all patients. Tru-cut biopsy was performed for diagnosis in most of the cases. Diagnosis in five patients (27.8%) required open biopsy. Results: DLBCL (77.8%) was the most common histological type among all patients. Other histological subtypes were anaplastic large cell lymphoma (11.1%), Burkitt-like lymphoma (5.6%) and marginal zone lymphoma (5.6%). According to Ann Arbor staging system, 44.4% of patients were Stage I, 11.1% were Stage II and 44.4% were Stage IV. Bone marrow involvement was determined in four patients (22.2%). All patients except one were treated with anthracycline-containing regimens and eight patients (44.4%) received rituximab combination with chemotherapy. Radiation therapy was performed as the first-line therapy in 9 (50%) patients. The median follow-up was 37 months (range, 2-124 months). Among the 17 patients who achieved complete remission, five (27.8%) relapsed. All patients were still alive. The five-year relapsefree survival was 73.5%. Conclusion: The treatment of bone lymphoma can be planned according to the stage and location of the disease. Although we had a relatively low number of patients, it could be concluded that whether or not radiation therapy is performed, rituximab in combination with systemic chemotherapy has been proven beneficial on survival.

Primary non-Hodgkin's lymphoma of bone. A clinicopathologic study

Cancer, 1994

A retrospective analysis of patients presenting with primary lymphoma of bone (PLB) was performed to determine clinical factors affecting prognosis in relation to histological subtype and treatment outcome. Data from 106 patients, presenting with a PLB between 1943 and 1996, were retrieved from the files of the Netherlands Committee on Bone Tumours and Leiden University Medical Centre. The lymphomas were reclassified according to the REAL and updated Kiel classification. The clinical presentation, survival and prognostic factors were investigated. Sixty patients had sufficient clinical information and adequate follow-up to be included in the study. All 33 PLB that could be immunophenotyped were of B cell origin. According to the REAL classification, most PLB were large (B) cell lymphomas (92%) and according to the Kiel classification 45% of the tumours were centroblastic multilobated. PLB presented most often in the long bones (48%), with Ann Arbor stage I (46%), II (16%), IV (16%) and unknown (20%). Stage IV disease was exclusively caused by the presence of multiple bone lesions. Notwithstanding the heterogeneous treatment, the 5year overall survival was 61%; 46% of patients were progression free at 5 years. Patients at presentation older than 60 had a worse overall survival (76% vs 37%, P ‫؍‬ 0.0002) and a worse progression-free period (58% vs 28%, P ‫؍‬ 0.0073). Patients with the immunoblastic subtype had a worse survival than the centroblastic mono/polymorphic subtype or the centroblastic multilobated subtype (P ‫؍‬ 0.015). Primary lymphoma of bone represents an uncommon bone tumour with a relatively homogeneous morphology and clinical behaviour. Compared to other aggressive lymphomas, PLB have a favourable prognosis.

PRIMARY BONE MARROW B-CELL LYMPHOMA: AN UNUSUAL PRESENTATION OF NON HODGKIN’S LYMPHOMA

National Journal of Medical Research, 2019

Non-Hodgkin’s lymphoma (NHL) presenting as primary bone marrow Lymphoma is very rare. Herewe have described a 40 year old HIV positive patient presenting with right sided parietal boneswelling.MRI brain was done which revealed bony tumor. FNAC was suspicious of lymphoproliferative disorder for which true cut biopsy was done. Biopsy was suspicious for NHL. Immunohistochemistry results were consistent with Diffuse large B Cell lymphoma, post germinal type.

Primary bone lymphomas—Clinical cases and review of literature

Journal of Bone Oncology, 2013

Primary bone lymphoma (PBL) is an uncommon clinical entity and a rare presentation of non-Hodgkin's lymphoma. PBL accounts for less than 5% of malignant bone tumors, 4-5% of extra nodal lymphoma and less than 1% of all non-Hodgkin's lymphoma. Diffuse large-B-cell lymphoma (DLBCL) accounts for the majority of cases of PBL. The incidence of PBL is so rare that many of its aspects remain unknown. A number of studies have been reported from western countries but only a few reports are available from Asia. Out of 20,000 bone lesions received in our department over 5 years, only 5 cases were primary bone lymphoma; all of which were DLBCL. We report our experience on PBLs with main emphasis on two unusual presentations of this rare tumor.

Primary bone lymphoma: A retrospective analysis

International Journal of Oncology, 2006

The aim of this study was to retrospectively define those patients with unequivocal primary bone lymphoma presenting to the Sheffield Lymphoma Group and document patient and tumour characteristics and management strategies, and correlate these with survival. Thirty-seven patients were documented from a total of 3148 cases of non-Hodgkin's lymphoma seen over 34 years. There were 17 males and 20 females, with a mean age of 55.4 years (range, 27-78). Pain was the most commonly presented symptom (67.5%), and the pelvis was the most frequently presented site (21.3%). Grade 2 and diffuse large B cell lymphoma comprised the majority of histologies (78.7% and 70.3%, respectively). Treatment was most often with radiotherapy alone (41.8%) or combined with CHOP-like chemotherapy (37.9%). The overall response rate was 56.7%, and 5-and 10-year survival rates were 64.5% and 49.6%, respectively. Univariate analysis showed an age of <60 years and complete response to be favourable prognostic factors. There was a trend toward better survival with combined modality therapy involving CHOP-like chemotherapy. Bone lymphoma has a better survival than other extranodal lymphomas. Younger age and complete response are favourable predictive factors. Combined modality treatment is likely to be the treatment of choice but this remains to be confirmed in large prospective multicentre studies.

Primary Lymphoma of Bone: A case report and brief review of literature

Clinical Case Reports and Reviews, 2017

Skeletal manifestations of Non-Hodgkin Lymphoma (NHL) is unusual, occurring in less than 5% of NHL cases; and primary non-Hodgkin lymphoma of bone (PLB) is rare, usually diffuse large B-cell lymphoma. PLB generally presents with localised bone pain, or, less frequently, soft tissue swelling. Pathological fractures, well documented in soft tissue sarcomas, are unusual in PLB. We report a case of polystotic PLB that presented with involvement of left anterior tibia (with pathologic facture) and left frontal skull.

Primary Bone Non-Hodgkin’s Lymphoma: A Literature Review

2021

Primary Bone Lymphoma (PBL) according to the World Health Organization (WHO) is a single skeletal lymphoma with or without lymph node involvement and multiple bone lesions without visceral or lymph node involvement. The etiopathogenesis of this disease remains unclear and requires further research. Literature search was done using search engines from Pubmed, Google Scholar, Cochrane Library, Web of Science, popular premier orthopedic journals (JBJS, BJJ, CORR, INJURY, ABJS, ActaOrthopedica, IJO) and general medical journals (JAMA, NEJM, Lancet) in the last 5 year, but relevant older articles were included. The diagnosis of PBL is confirmed by clinical examination, radiological support and biopsy. Standard management to date includes immunochemotherapy with or without radiotherapy, while operative measures are limited to biopsy sampling and stabilization of pathologic fractures or impending fractures with risks above intermediate. A good prognosis is found in PBL patients with Diffus...